Category: Biotech

Biotech • 10.10.25

Bristol Myers Squibb's $1.5 Billion Bet: A New Frontier in RNA and Cell Therapy

Bristol Myers Squibb's $1.5B acquisition of Orbital Therapeutics signals a major shift towards RNA and cell therapy platforms, impacting biotech M&A and drug development.

StockTimes Content Team

1
Finance • 23.04.25

US Stock Market Downturn: A Buying Opportunity or a Warning Sign?

StockTimes Content Team
Cryptocurrency • 08.04.25

SOL Strategies Expands Solana Staking with Major SOL Purchase

StockTimes Content Team
Politics • 28.03.25

Can Germany’s SPD and CDU Overcome Differences to Form a Grand Coalition?

StockTimes Content Team
Business • 29.04.25

BP’s Strategic Reset: Profit Drop, Activist Pressure, and Future Prospects

StockTimes Content Team
Cryptocurrency • 07.04.25

XRP, ADA, DOGE Plunge Below Key Support Levels Amid Market Turmoil

StockTimes Content Team
Cryptocurrency • 10.11.25

The Privacy Renaissance: How zenZEC is Unlocking Zcash for Solana's DeFi Ecosystem

StockTimes Content Team

Categories

Tags